EquiLend Holdings LLC – Trademark Portfolio
Entity Type: 16
EquiLend Holdings LLC holds 21 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 21 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 10 trademarks are registered. Notable registered marks include NGT, DL50, DLNH25, ORBISA, and BONDLEND. The owner is based in New York, NY.
225 Liberty Street, 10th Floor
New York, NY 10281
Showing of trademarks Trademarks
Trademark Classifications
EquiLend Holdings LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does EquiLend Holdings LLC have?
EquiLend Holdings LLC has 21 U.S. trademarks filed with the USPTO. Of these, 10 registered, 4 abandoned, 7 cancelled.
What trademark classes does EquiLend Holdings LLC file in?
EquiLend Holdings LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are EquiLend Holdings LLC's most well-known trademarks?
EquiLend Holdings LLC's registered trademark portfolio includes well-known marks such as NGT, DL50, DLNH25, ORBISA, and BONDLEND. These are among 10 currently registered trademarks in the portfolio.
What is EquiLend Holdings LLC's trademark registration success rate?
EquiLend Holdings LLC has a 48% trademark registration rate, with 10 out of 21 resolved applications resulting in successful registration. Currently, 0 applications are pending review.